ABSTRACT
Objective:To investigate the clinical efficacy and safety of chidamide monotherapy or its combination of chemotherapy in the treatment of peripheral T-cell lymphoma (PTCL).Methods:The clinical data of 40 cases PTCL patients (26 cases newly diagnosed PTCL and 14 cases relapsed/refractory PTCL) treated with chidamide between December 2015 and April 2019 in Shanxi Provincial Cancer Hospital were retrospectively analyzed. The overall response rate (ORR), progression-free survival (PFS), overall survival (OS) of the patients were observed, and the adverse reactions were analyzed.Results:ORR of all patients was 70.0% (28/40), ORR of the newly diagnosed group was 80.8% (21/26), ORR of the relapsed/refractory group ORR was 50.0% (7/14). The short-term efficacy of the newly diagnosed group was better than that of the relapsed/refractory group ( P = 0.049). The ORR of prognostic index for PTCL (PIT) 0-1 score group was 83.3% (10/12), PIT 2-4 score group was 78.6% (11/14); the therapeutic efficacy of PIT 0-1 score group was better than that of PIT 2-4 score group, and the difference between the two groups was not statistically significant ( P = 0.578). ORR of angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (PTCL-NOS) subtype in the newly diagnosed group was 90.0% (9/10). The median follow-up time was 14.5 months. The median PFS time was 12 months in the newly diagnosed group, 1-year PFS rate and OS rate was 49.6% and 84.2%, 2-year PFS rate and OS rate was 35.9% and 57.4%. The median PFS time was 7 months in the relapsed/refractory group, 1-year PFS rate was 28.6%, 1-year OS rate was 49.0%. There was no Ⅲ-Ⅳ neutropenia and Ⅲ-Ⅳ gastrointestinal reaction in the chidamide monotherapy group; the incidence of Ⅲ-Ⅳdegree neutropenia was 39.4% (13/33) in the chidamide combined with chemotherapy. The incidence of Ⅲ-Ⅳ degree gastrointestinal response rate was 27.3% (9/33), and there was no Ⅲ-Ⅳ degree of liver and kidney dysfunction. Conclusion:Chidamide has good short-term efficacy in newly treated or relapsed/refractory PTCL patients. All patients are well tolerated with chidamide monotherapy or its combination of chemotherapy.
ABSTRACT
Objective To explore the expression of b-cell lymphoma/leukemia-2 (bcl-2) and breast cancer drug-resistant protein (BCRP) in diffuse large B cell lymphoma (DLBCL) and their correlation. Methods Using flow cytometry (FCM) and semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) assay the expressions of BCRP gene was analysed in 40 DLBCL samples. bcl-2 protein were measured by immunohistochemistry on paraffin-embedded slices in 40 cases of DLBCL. Results The positive expression rate of bcl-2 and BCRP protein were 60.0 % (24/40) and 37.5 % (15/40) in 40 patients with DLBCL respectively. There was significant differences between positive group and negative groups (x2 = 5.7618,P 0.05). Conclusion BCRP may play an important role in DLBCL primary much medicine drug-resistant,thus it may be a useful prediction of chemotherapeutic treatment and risk of relapse. The level bcl-2 expression was closely related with the grade of malignancy and the prognosis of DLBCL. There was no significant correlation between bcl-2 and BCRP gene. The detection of bcl-2 and BCRP gene played an important role in evaluating DLBCL outcome.